Abstracts tagged "glucocorticoids"

Abstract Number: 2429 • ACR Convergence 2023
Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
Chi Chiu Mok¹, SAU MEI TSE², Kar Li Kelly Chan³ and Wai Han Ma¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, China, ³Tuen Mun Hospital, Shatin, China
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients treated with glucocorticoids (GCs). Methods: Adult patients (≥18 years)…
Abstract Number: 0163 • ACR Convergence 2023
Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims
Jing Li¹, Julia Kay¹, Sharon Abada¹, Andriko Palmowski², Rachael Stovall¹, Jinoos Yazdany³ and Gabriela Schmajuk⁴, ¹University of California San Francisco, San Francisco, CA, ²Charité - Universitätsmedizin Berlin, Berlin, Germany, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: Understanding glucocorticoid (GC) exposure is critical for observational analyses in rheumatology. However, obtaining an accurate measure of GC exposure, including dosage and duration, has…
Abstract Number: 1488 • ACR Convergence 2023
Association of Glucocorticoid Use with Patient-Reported Outcomes Among Persons with Systemic Lupus Erythematosus
Patti Katz¹, Sofia Pedro², Jiyoon Choi³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Rafael, CA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for SLE. While GCs do provide benefit, there are potential side effects that increase with…
Abstract Number: 2430 • ACR Convergence 2023
Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², H. Myra Kim¹, Bryant England³, Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Punyasha Roul³, Ted R Mikuls⁷, Shirley Cohen-Mekelburg¹, Daniel Clauw⁸, Wyndy Wiitala², Rodney Hayward¹, Jeremy Sussman¹ and Akbar Waljee⁹, ¹VA Ann Arbor; University of Michigan, Ann Arbor, MI, ²VA Ann Arbor, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁹VA Ann Arbor, University of Michigan, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events…
Abstract Number: 0207 • ACR Convergence 2023
Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Fadi Shehadeh², Markos Kalligeros¹ and Eleftherios Mylonakis³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, ²Houston Methodist Research Institute, Houston, TX, ³Department of Medicine, Houston Methodist Hospital, Houston, TX
Background/Purpose: Available immunosuppressive treatments for autoimmune inflammatory rheumatic diseases (AIRD) might increase the risk for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). Prophylactic trimethoprim-sulfamethoxazole…
Abstract Number: 1566 • ACR Convergence 2023
Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
Christine Xu¹, Ying Liu¹, Jennifer Sloane², Remco Diab³, Hubert van Hoogstraten¹, Hisham Abdallah⁴, Sreeraj Macha¹ and Bhaskar Dasgupta⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Cambridge, MA, ³Sanofi, Rotkreuz, Switzerland, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
Abstract Number: 2516 • ACR Convergence 2023
The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica
Katrina Nguyen¹, Jennifer Du¹, Jiaxiao shi² and Antony Lin¹, ¹Kaiser SCAL, Fontana, CA, ²SCPMG, Pasadena, CA
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
Abstract Number: 0271 • ACR Convergence 2023
Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients
Huaqun Zhu, Sumei Tang, Yun Li, Feng Sun, Yuzhou Gan and Hua Ye, Peking University People’s Hospital, Beijing, China
Background/Purpose: Our observational cohort study aimed at assessing the effectiveness and safety of the Janus kinase (JAK) inhibitor tofacitinib in refractory IgG4-Related Disease (IgG4-RD).Methods: Seven…
Abstract Number: 1729 • ACR Convergence 2023
An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases
Yuhao Qin¹, Wenming Ren², Liangqin Tong³, lu su³ and cheng liao³, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China, ²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pudong New District, China, ³Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
Background/Purpose: Tumor necrosis factor α (TNFα) is a pivotal pro-inflammatory cytokine. And TNF inhibitors are the most successful anti-rheumatic drugs for the treatment of autoimmune…
Abstract Number: 2530 • ACR Convergence 2023
Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Sarah Keller¹, Adil Vural², Jennifer Varley², Komal Mushtaq², Walaa Abu Alya³, Neel Tapryal², Hassan Shaheen³, Marie Budev², Abby Abelson² and Chad Deal¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Fairview Hospital, Cleveland, OH
Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…
Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Naomi Patel¹, Aubree McMahon¹, Grace McMahon¹, Sebastian Perez-Espina¹, Isha Jha¹, Adam Jarvie¹ and John Stone², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…
Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Smadar Gertel¹, Victoria Furer¹, Ari Polachek¹ and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
Abstract Number: 2531 • ACR Convergence 2023
Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Andriko Palmowski¹, Gabriela Schmajuk², Jinoos Yazdany³, Patti Katz⁴, Jing Li⁵, Rachael Stovall⁵, Emma Kersey⁵, Sabrina Mai Nielsen⁶, Robin Christensen⁷, Henning Bliddal⁸, Zhivana Boyadzhieva⁹, Udo Schneider⁹, Tobias Alexander¹⁰, Burkhard Muche¹¹, Sandra Hermann¹¹, Edgar Wiebe¹¹ and Frank Buttgereit¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²UCSF / SFVA, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of California San Francisco, San Rafael, CA, ⁵University of California San Francisco, San Francisco, CA, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁸The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁹Charité Universitatsmedizine - Berlin, Berlin, Germany, ¹⁰Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ¹¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…
Abstract Number: 0447 • ACR Convergence 2023
Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
Lucia Otero-Valera¹, Jose María Alvaro-Gracias², Jerusalem Calvo³, Cristina Campos⁴, Alicia Garcia Dorta⁵, Fernando Sánchez-Alonso⁶ and Isabel Castrejon⁷, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³Reina Sofia University Hospital, Córdoba, Spain, ⁴Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Fundación Española de Reumatología, Madrid, Spain, ⁷Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Glucocorticoids are frequently used as bridging therapy for rheumatoid arthritis (RA) patients starting conventional synthetic DMARDs. Both EULAR and ACR guidelines (1,2), recommend to…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…

« Previous Page
1
…
8
9
10
11
12
…
25
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].